ArticleJournal of Alzheimer's disease reports

Sentiment analysis of social media responses to the approval of lecanemab for the treatment of Alzheimer's disease in Japan.

Kenichiro Sato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.